Celgene's $1.1bn Impact Buy Is First Of More Deals To Come In 2018 And Beyond

 
• By Mandy Jackson

Celgene believes it's acquiring a $1bn drug, not a me-too JAK inhibitor in its purchase of Impact Biomedicines for $1.1bn up front. Investors appeared skeptical of fedratinib's potential, but the company said at the J.P. Morgan meeting that it will execute more deals to build out its pipeline.

Two businessmen shaking hands during a meeting in the office, success, dealing, greeting & business partner concepts - soft light.

More from Deals

More from Business